Can dabrafenib treat lung cancer?

Yes, Dabrafenib (Dabrafenib) is a BRAF kinase inhibitor that is used to treat patients with BRAF Non-small cell lung cancer (NSCLC) with V600E or V600K gene mutation. This gene mutation is relatively common in some NSCLC patients, and dabrafenib blocks the growth and spread of cancer cells by inhibiting the activity of BRAF kinase. In some clinical trials, dabrafenib has shown some efficacy in patients with NSCLC harboring these mutations. However, the choice of treatment options should still be based on the patient's specific condition, individual differences, and the professional advice of the doctor.